Brainstorm Cell Therapeutics, Inc. (BCLI)
1.065
-0.06
(-5.19%)
USD |
OTCM |
Aug 31, 16:00
Brainstorm Cell Therapeutics Cash from Operations (TTM) : -4.057M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.057M |
| March 31, 2026 | -6.664M |
| December 31, 2025 | -6.975M |
| September 30, 2025 | -7.283M |
| June 30, 2025 | -9.48M |
| March 31, 2025 | -7.661M |
| December 31, 2024 | -9.093M |
| September 30, 2024 | -11.33M |
| June 30, 2024 | -14.44M |
| March 31, 2024 | -19.54M |
| December 31, 2023 | -20.46M |
| September 30, 2023 | -21.82M |
| June 30, 2023 | -20.26M |
| March 31, 2023 | -19.62M |
| December 31, 2022 | -19.32M |
| September 30, 2022 | -20.18M |
| June 30, 2022 | -21.79M |
| March 31, 2022 | -20.98M |
| December 31, 2021 | -26.26M |
| September 30, 2021 | -28.34M |
| June 30, 2021 | -28.80M |
| March 31, 2021 | -29.13M |
| December 31, 2020 | -35.19M |
| September 30, 2020 | -30.89M |
| June 30, 2020 | -27.60M |
| Date | Value |
|---|---|
| March 31, 2020 | -25.44M |
| December 31, 2019 | -11.25M |
| September 30, 2019 | -11.69M |
| June 30, 2019 | -14.66M |
| March 31, 2019 | -11.10M |
| December 31, 2018 | -12.39M |
| September 30, 2018 | -11.60M |
| June 30, 2018 | -1.163M |
| March 31, 2018 | -2.848M |
| December 31, 2017 | -2.364M |
| September 30, 2017 | -0.625M |
| June 30, 2017 | -4.743M |
| March 31, 2017 | -4.519M |
| December 31, 2016 | -5.858M |
| September 30, 2016 | -5.953M |
| June 30, 2016 | -8.208M |
| March 31, 2016 | -8.452M |
| December 31, 2015 | -7.408M |
| September 30, 2015 | -8.124M |
| June 30, 2015 | -6.713M |
| March 31, 2015 | -6.033M |
| December 31, 2014 | -4.487M |
| September 30, 2014 | -4.088M |
| June 30, 2014 | -3.682M |
| March 31, 2014 | -3.775M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| NovelStem International Corp. | -0.2295M |
| Summit Therapeutics, Inc. | -457.02M |
| Kezar Life Sciences, Inc. | -42.03M |
| Protara Therapeutics, Inc. | -66.13M |
| Clene, Inc. | -15.96M |